STUDY OBJECTIVE: To determine whether changes in serum @entity413 , serum @entity972 , and plasma @entity2690 levels are correlated in a cohort of @entity101 @entity1 . DESIGN: Prespecified subgroup analysis of results from a prospective, multicenter, randomized, open-label, parallel-group study. Setting. Primary care clinics at three tertiary care medical centers. @entity1 : Community-based ambulatory population of 202 @entity1 (age range 17-65 yrs) with a new diagnosis of @entity101 , untreated @entity101 , or known @entity101 , who were previously treated with fewer than three antihypertensive drugs and had no evidence of @entity65 or @entity6 . Intervention. Monotherapy with oral @entity918 12.5 or 25 mg/day for 9 weeks. MEASUREMENTS AND MAIN RESULTS: Fasting serum @entity413 , serum @entity972 , and plasma @entity2690 levels were obtained at baseline (before @entity918 therapy was started) and after 9 weeks of therapy. Significant elevations were noted in fasting serum @entity413 (mean +/- SD 3.42 +/- 10.38 mg/dl, p<0.0001) and plasma @entity2690 (2.35 +/- 9.47 microU/ml, p<0.0001) levels, and a significant reduction in serum @entity972 level (0.30 +/- 0.44 mEq/L, p<0.0001) was noted. No significant correlation was observed between changes in fasting serum @entity413 and @entity972 levels (r = 0.022, 95% confidence interval (CI) -0.120-0.164, p=0.757) or between changes in serum @entity972 and plasma @entity2690 levels (r = -0.112, 95% CI -0.256-0.037, p=0.140). Changes in serum @entity413 levels did not differ significantly between patients maintaining serum @entity972 levels of 4.0 mEq/L or greater and those with levels below 4.0 mEq/L. CONCLUSION: Changes in serum @entity972 and serum @entity413 levels were not correlated in individuals receiving @entity918 monotherapy; thus maintenance of normal @entity972 levels may not attenuate the risk of @entity6662 diuretic-induced @entity4854 .

Lack of correlation between XXXX -induced @entity4854 and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity918 :: ('MESH:D006852', 'Chemical') :: ['hydrochlorothiazide'] @entity2690 :: ('3630', 'Gene') :: ['insulin'] @entity6662 :: ('D049971', 'Chemical') :: ['thiazide'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity6662 :: (D049971,Chemical) :: ['thiazide']
